The purpose of this Funding Opportunity Announcement (FOA) is to support the development and validation of modeling and simulation methods and related tools to examine HIV transmission dynamics, make epidemic projections, and estimate the impact of HIV treatment and prevention. Investigators are expected to share these resources with other researchers. Funding for the final fourth year is dependent upon achieving applicant-proposed and pre-award negotiated "Go/No-Go criteria".

The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support Developmental AIDS Research Centers (D-ARC). The D-ARC is intended to provide infrastructural support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission.

The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support an HIV/AIDS Research Center (ARC). The ARC is intended to provide infrastructural support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission.

This Funding Opportunity Announcement (FOA) seeks to bring together investigators with complementary expertise in HIV and in gastrointestinal mucosal pathobiology to dissect fundamental processes within the gastrointestinal tract that impact HIV infection, persistence, and comorbidities. This multidisciplinary approach should lead to comprehensive, in-depth mechanistic analyses and advance progress toward alleviating comorbidities that afflict people living with HIV and toward developing a cure.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA requires an industry partner, milestones linked to Go/No Go decisions and year 5 funding requires communication with/ pre-IND submission to the FDA.